<DOC>
	<DOC>NCT00859898</DOC>
	<brief_summary>The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study</brief_summary>
	<brief_title>Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Treatment naive males and females, &gt;= 18 years old and &lt;= 77 years old, with type 2 diabetes mellitus Subjects must have central laboratory prerandomization hemoglobin A1C &gt;= 7.5 and &lt;= 12.0% Cpeptide &gt;= 1.0 ng/mL (0.34 nmol/L) Body Mass Index &lt;= 45 kg/m2 Must be able to perform self monitoring of blood glucose aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;3X*upper limit of normal (ULN) Serum Total bilirubin &gt;2 mg/dL (34.2 µmol/L) Creatinine kinase &gt;3*ULN Serum creatinine &gt;= 1.50 mg/dL (133 µmol/L) for male subjects, &gt;= 1.40 mg/dL (124 µmol/L) for female subjects Calcium value outside of the central laboratory normal reference range Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases Urine albumin:creatinine ratio (UACR) &gt;1800 mg/g (203.4 mg/mmol Cr) Severe uncontrolled hypertension defined as systolic blood pressure (SBP) &gt;=180 mmHg and/or diastolic blood pressure (DBP) &gt;=110 mmHg Hemoglobin &gt;=11.0 g/dL (110 g/L) for men; hemoglobin &gt;=10.0 g/dL (100 g/L) for women Positive for hepatitis B surface antigen Positive for antihepatitis C virus antibody History of diabetes insipidus History of diabetic ketoacidosis or hyperosmolar nonketotic coma Symptoms of poorly controlled diabetes that would preclude participation in this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>